Case Report and Clinical Reasoning: Fulminant Liver Failure and Invasive Aspergillosis Following Ocrelizumab Treatment in a 21 Year-Old Woman

Overview

Journal Neurohospitalist

Publisher Sage Publications

Date 2022 Dec 19

PMID 36531849

Authors

Caleb R S McEntire

Cammie F Lesser

Nagagopal Venna

Affiliations

Soon will be listed here.

Abstract

We present the case of a 21 year-old woman with newly diagnosed relapsing-remitting multiple sclerosis who is given a single dose of ocrelizumab and placed on moderate-dose steroids with subsequent development of hepatic failure who goes on to develop highly fulminant systemic and central nervous system (CNS) aspergillosis. Ocrelizumab has no documented association with aspergillus infection, and moderate-dose steroids less often lead to such fulminant disease, but liver failure is associated with often-fatal aspergillus infection. We emphasize that liver failure is an underrecognized immune dysregulated state that predisposes to bacterial and fungal infections and suggest changes in diagnostic reasoning that could be considered in patients with multiple modalities of immunosuppression.

References

Marr K, Carter R, Crippa F, Wald A, Corey L . Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002; 34(7):909-17. DOI: 10.1086/339202. View

Ruhnke M, Kofla G, Otto K, Schwartz S . CNS aspergillosis: recognition, diagnosis and management. CNS Drugs. 2007; 21(8):659-76. DOI: 10.2165/00023210-200721080-00004. View

Thompson A, Banwell B, Barkhof F, Carroll W, Coetzee T, Comi G . Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2017; 17(2):162-173. DOI: 10.1016/S1474-4422(17)30470-2. View

Rolando N, Harvey F, Brahm J, Philpott-Howard J, Alexander G, Casewell M . Fungal infection: a common, unrecognised complication of acute liver failure. J Hepatol. 1991; 12(1):1-9. DOI: 10.1016/0168-8278(91)90900-v. View

Chen J, Yang Q, Huang J, Li L . Risk factors for invasive pulmonary aspergillosis and hospital mortality in acute-on-chronic liver failure patients: a retrospective-cohort study. Int J Med Sci. 2013; 10(12):1625-31. PMC: 3804788. DOI: 10.7150/ijms.6824. View

Fernandez J, Acevedo J, Wiest R, Gustot T, Amoros A, Deulofeu C . Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis. Gut. 2017; 67(10):1870-1880. DOI: 10.1136/gutjnl-2017-314240. View

Aisner J, Wiernik P, Schimpff S . Treatment of invasive aspergillosis: relation of early diagnosis and treatment to response. Ann Intern Med. 1977; 86(5):539-43. DOI: 10.7326/0003-4819-86-5-539. View

Proulx N, Frechette D, Toye B, Chan J, Kravcik S . Delays in the administration of antibiotics are associated with mortality from adult acute bacterial meningitis. QJM. 2005; 98(4):291-8. DOI: 10.1093/qjmed/hci047. View

Taylor N, Nishtala A, Manakkat Vijay G, Abeles R, Auzinger G, Bernal W . Circulating neutrophil dysfunction in acute liver failure. Hepatology. 2012; 57(3):1142-52. DOI: 10.1002/hep.26102. View

10.

Parody R, Martino R, Sanchez F, Subira M, Hidalgo A, Sierra J . Predicting survival in adults with invasive aspergillosis during therapy for hematological malignancies or after hematopoietic stem cell transplantation: Single-center analysis and validation of the Seattle, French, and Strasbourg prognostic indexes. Am J Hematol. 2009; 84(9):571-8. DOI: 10.1002/ajh.21488. View

11.

Wu Z, Ling Z, Shao F, Sheng J, Li L . Invasive pulmonary aspergillosis in patients with acute-on-chronic liver failure. J Int Med Res. 2012; 40(5):1958-65. DOI: 10.1177/030006051204000537. View

12.

Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J . Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013; 144(7):1426-37, 1437.e1-9. DOI: 10.1053/j.gastro.2013.02.042. View

13.

Leeflang M, Debets-Ossenkopp Y, Visser C, Scholten R, Hooft L, Bijlmer H . Galactomannan detection for invasive aspergillosis in immunocompromized patients. Cochrane Database Syst Rev. 2008; (4):CD007394. DOI: 10.1002/14651858.CD007394. View

14.

Lamoth F, Cruciani M, Mengoli C, Castagnola E, Lortholary O, Richardson M . β-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3). Clin Infect Dis. 2011; 54(5):633-43. DOI: 10.1093/cid/cir897. View

15.

Wasmuth H, Kunz D, Yagmur E, Timmer-Stranghoner A, Vidacek D, Siewert E . Patients with acute on chronic liver failure display "sepsis-like" immune paralysis. J Hepatol. 2005; 42(2):195-201. DOI: 10.1016/j.jhep.2004.10.019. View

16.

Caldito N, Shirani A, Salter A, Stuve O . Adverse event profile differences between rituximab and ocrelizumab: Findings from the FDA Adverse Event Reporting Database. Mult Scler. 2020; 27(7):1066-1076. DOI: 10.1177/1352458520949986. View

17.

von Eiff M, Roos N, Schulten R, Hesse M, Zuhlsdorf M, van de Loo J . Pulmonary aspergillosis: early diagnosis improves survival. Respiration. 1995; 62(6):341-7. DOI: 10.1159/000196477. View

18.

Montalban X, Hauser S, Kappos L, Arnold D, Bar-Or A, Comi G . Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2016; 376(3):209-220. DOI: 10.1056/NEJMoa1606468. View

19.

Hauser S, Bar-Or A, Comi G, Giovannoni G, Hartung H, Hemmer B . Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med. 2016; 376(3):221-234. DOI: 10.1056/NEJMoa1601277. View

20.

Nicolini L, Canepa P, Caligiuri P, Mikulska M, Novi G, Viscoli C . Fulminant Hepatitis Associated With Echovirus 25 During Treatment With Ocrelizumab for Multiple Sclerosis. JAMA Neurol. 2019; 76(7):866-867. PMC: 6583842. DOI: 10.1001/jamaneurol.2019.0522. View